期刊
CLINICAL RHEUMATOLOGY
卷 22, 期 4-5, 页码 329-332出版社
SPRINGER-VERLAG
DOI: 10.1007/s10067-003-0716-3
关键词
chronic myelogenous leukemia (CML); protein tyrosine kinase (PTK); platelet-derived growth factor (PDGF); rheumatoid arthritis (RA); signal transduction inhibitor (STI) 571
类别
We report on an 80-year-old man with rheumatoid arthritis (RA) who presented with chronic myelogenous leukemia (CML). Five years after the onset of RA, the CML diagnosis was made. The patient was treated for CML with 300 mg of imatinib mesylate (STI; signal transduction inhibitor 571) for 8 weeks. Laboratory tests showed that the C-reactive protein level, percentage of cells exhibiting the Philadelphia chromosome (Phl), WBC count, and Lansbury index for RA all dropped respectively from 7.5 mg/dl to 1.0 mg/dl, 74.9% to 1%, 25, 100/mul to 9900/mul, and 51% to 14%. Administration of imatinib mesylate is felt to be effective in treating not only CML but also RA in the active stage.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据